FI95578B - Process for the activating of gene-technologically produced, heterologous, disulphide bridge-containing eukaryotic proteins after expression in prokaryotes - Google Patents

Abstract

Method for activating non-glycosylated tissue plasminogen activator (t-PA) after its expression in prokaryotic cells comprises cell lysis; solubilisation under denaturing and reducing conditions, and reactivation under oxidising conditions in presence of reduced and oxidised glutathione (G5H, G55G). The new feature is that in the last stage is at pH 9-12 (pref. 9.5-11) with G5H and G55G concns. 0.1-20, pref. 0.2-10, mM and 0.01-3, pref. 0.5-1, mM, respectively, and with a non-denaturing concn. of the denaturing agent. Esp. the method is applied to t-PA expressed in E.coli and P. putida. The denaturing agent is pref. arginine, guanidine hydrochloride (both at 0.1-1, esp. 0.25-0.75, mM) or urea, at 0.5-4 (esp. 1-3.5) M in the last stage.

Description

5,95578

Method for activating genetically engineered heterologous eukaryotic proteins comprising disulfide bridges in prokaryotes after expression This application is divided by division from application 872753.

The invention relates to a method for activating genetically engineered eukaryotic proteins containing disulfide bridges after expression in prokaryotes.

When expressing heterologous proteins in prokaryotes, these proteins often form inactive, sparingly soluble clumps (so-called refractile bodies) in host cells, and further comprise host cell proteins as impurities. It is hypothesized that the formation of such "refractive bodies" is due to the high protein content of the 20 cells upon expression. It is known that when large amounts of enzymes are formed in a cell, these enzymes accumulate into insoluble, high molecular weight, most often inactive particles. Thus, before such proteins can be used, for example, for therapeutic purposes, they must be purified and brought into active form.

Reactivation of such agglomerated proteins can be accomplished according to known methods in several steps (see, e.g., R.).

30 Jaenicke, FEBS Federation of European Biochemical Societies, Vol. 52 (1979) 187-198; R. Rudolph et al., Biochemistry 18. (1979) 5572-5575):

In the first step, the protein is solubilized by adding a strong denaturant, for example guanidine hydrochloride or urea in high concentrations, or by adding strongly acidic substances, for example mixtures of glycine * and phosphoric acid. Reducing SH reagents (e.g., dithioerythritol, DTE) and EDTA have been found to be useful excipients, e.g., for renaturation of LDH protein. If the protein contains host cell proteins as an impurity, then the next step is purification by conventional methods known per se, for example by gel or ion exchange chromatography. The protein is then diluted vigorously to reduce the concentration of denaturant. When guanidine hydrochloride is used, the protein is diluted to less than 0.5 mol / L. In the case of enzymes with free SH groups, the addition of SH-protecting agents has proved advantageous (see, for example, R. Jaenicke, Journal of Polymer Science, Part C 16 (1967) 2143-2160).

15

EP-A 0 114 506 describes a method for isolating and purifying certain heterologous expressed products from bacterial cultures and reactivating these products: to reactivate the product, solutions of "refractive bodies" in a strongly denaturing agent are a) directly converted into to restore; b) the protein is sulfonated and then dissolved in a weakly dena-swelling agent, after which the S-sulfonate groups are converted to their reduced and oxidized form by treatment with a sulfhydryl reagent, for example GSH / GSSG reagent, to -S-S groups; or c) the solution in the weakly denaturing agent is treated directly with a sulfhydryl reagent, for example GSH / GSSG. A typical example of encountering the difficulties described above is t-PA.

The major component in the coagulated blood protein matrix is polymeric fibrin. This protein matrix is soluble by the action of plasmin, which is formed from plasminogen as a result of the activation of so-called plasminogen activators, for example t-PA (tissue type plasminogen activator; 95578 minogen activator). The enzymatic activity (catalytic activation of plasminogen to plasmin) of natural t-PA or genetically engineered t-PA from eukaryotes is very low in the absence of fibrin or fibrin cleavage products (FPTs), but this activity is substantially increased (more than 10-fold) acid. This so-called stimulatability of activity is a crucial advantage of t-PA over other known plasminogen activators, such as urokinase or streptokinase (see, for example, M. Hoylaerts et al., J. Biol. Chem. 257 (1982) 2912-2919; Nieuwenhuizen et al. ai., Biochemica et Biophysica Acta 755 (1983) 531-533. Thus, various coefficients for stimulatory activity using BrCN-pilk-15 accumulation products are reported in the literature, with this coefficient reaching 3 5.

a t-PA-like, non-glycosylated product is also induced to form in genetically engineered prokaryotes 20 (after cDNA implantation); however, the activity of this product is not stimulable like e-karyotic-derived t-PA. This is possibly due to the fact that the oxidation-reduction conditions in the prokaryotic cell differ from those in the eukaryotic cell from which the gene is derived, so that the prokaryote initially forms an inactive product. This, in turn, may be due, for example, to the fact that the numerous SS bridges contained in the natural, active molecule are incorrectly coupled, or not formed at all. A prerequisite for the therapeutic use of t-PA is not only its enzymatic activity per se, but also its stimulability. In The EMBO Journal 4, Nr. 3 (1985) 775-780 emphasizes, in the case of other substances, the fact that prokaryotic cells are unlikely to be provided with the appropriate conditions under which the activity of eukaryotic proteins would be properly generated.

4,95578

According to EP-A 0 093 639, the reactivation of t-PA is carried out by suspending cell pellets obtained from E. coli cells in 6 mol / l guanidine hydrochloride, sonicating them, incubating them and then dialyzing them. four hours against Tris-HCl (pH 8.0), EDTA and Tween 80 and sodium chloride solution. After dialysis, the preparation is centrifuged, after which the plasminogen activator is found in the supernatant. Although t-PA renated in this way is proteolytically active, its stimulability with fibrin-derived BrCN cleavage products (BrCN-FPT) is still below the measurement threshold using the method described in J. H. Verheijen, Thromb. Haemostas., 48, (3), 15 260-269 (1982).

At present, no commonly used method for reactivating denatured proteins is known in the art; this is especially true for t-PA because the 20 natural proteins are very complex in structure. It contains a free thiol group and 17 SS bridges, which could theoretically be linked in 2.2 x 1020 different ways, with only a single structure corresponding to the natural state of the protein. However, methods currently known in the art for reactivating t-PA yield a proteolytically active t-PA protein that does not have measurable stimulation. There is no known method in the art for activating a stimulable t-PA protein.

Accordingly, it is an object of the present invention to provide a method for the complete activation of genetically engineered heterologous eukaryotic proteins comprising disulfide bridges after expression in prokaryotes. This object is achieved by the method which is the subject of the present invention.

5,95578

The invention relates to a method according to claim 1 for the activation of genetically engineered heterologous disulfide bridged and eukaryotic proteins after expression in prokaryotes by disrupting the cells, solubilizing the protein under denaturing and reducing conditions, and activating (renaturing) in the presence of a reagent which is characterized in that the pH prevailing in the activation step is 8-12, the GSH content is 0.1-20 mmol / l, the GSSG content is 0.01-3 mmol / l, and a denaturant which selected from the group consisting of arginine, methyl urea, ethyl urea, dimethyl urea, formamide, methyl formamide, acetamide, propionamide and butyramide, are used in non-denaturing concentrations.

Other claims relate to other preferred embodiments of this method.

As the denaturing agent, a denaturing agent commonly used for activating proteins under oxidizing conditions, or arginine, can be usually used; of the known denaturants, guanidine hydrochloride or urea or their derivatives are preferably used. In addition, arginine has been found to be suitable. Furthermore, mixtures of these denaturing agents can be used. This activation step is preferably further performed in the presence of a foreign protein; ‘A suitable foreign protein can generally be any protein that is not proteolytically active. The method preferably uses bovine serum albumin (BSA) in an amount of, for example, 1-3 mg / ml. The addition of BSA results in a slight increase in yield and stabilizes the protein (probably due to the foreign protein protecting the surface from denaturation and / or proteolytic degradation).

Other conditions in the process may correspond to known and conventional conditions in the reactivation steps of the prior art. The activation time (incubation time) is preferably 20-48 hours at room temperature. The half-life of activation in the presence of 0.5 mmol / 165,578 reduced (GSH) and oxidized (GSSG) glutathione is about 10-15 hours at 20 ° C. If the incubation is continued for a longer time (48 hours) under re-oxidizing conditions, the stimulability with BrCN cleavage products 5 is usually reduced. The activation step is preferably performed in the presence of EDTA, with the most appropriate concentration being about 1 mmol / L EDTA.

In the process, the steps before and after the activation step (reoxidation / activation), such as cell disruption, solubilization (solubilization / reduction), and purification steps, possibly before and / or after the activation step, can be carried out according to the prior art, e.g. or EP-A 0 093 619 according to known and conventional methods for such measures. However, for optimum results in terms of yield and activation, it may be appropriate to carry out some or all of the steps of the method in accordance with one or more of the embodiments set forth herein. It is also possible, in particular, that the activation step according to the invention is carried out with the mixture obtained after disruption of the cells without prior denaturation and / or reduction, but the yield is still low. Expression is carried out in prokaryotes, preferably P. putida and especially E. coli. However, the method of the invention can be used just as well when the expression is carried out in other prokaryotes (e.g. bacilli).

30

Disruption of the cells can be accomplished for this purpose by conventional methods, for example, ultrasound, high-pressure dispersion, or lysozyme. The cells are usually disrupted in a suitable buffer medium, such as Tris-HCl, at a concentration of 0.1 mol / l to provide a neutral or weakly acidic pH of 35. After disruption of the cells, the insoluble material ("refractive bodies") is separated in the desired manner, preferably by centrifugation using high g-values and long centrifugation times, or by filtration. The agglomerate is washed with substances which do not interfere with the t-PA protein but which nevertheless potentially dissolve 5 foreign cellular proteins, for example water or phosphate buffer solution to which possibly dilute surfactants such as Triton have been added, after which the agglomeration (pellet) is soluble (solubilization / deoxidating-ION). The solubilization is preferably carried out in an alkaline pH range, in particular at a pH of 8.6 + 0.4, in the presence of a reducing agent derived from the mercaptan group and a denaturing agent.

As the denaturing agent, conventional denaturing agents, in particular guanidine hydrochloride or urea, known from the prior art, for example according to EP-A 0 114 506, can be used. The concentration of guanidine hydrochloride is suitably about 6 mol / l, and of urea about 8 mol / l. Compounds of general formula I can likewise be used in the process.

As the reducing agent derived from the mercaptan group, for example, reduced glutathione (GSH) or 2-mercaptoethanol can be used, for example in a concentration of about 50 to 400 mmol / l, and / or in particular dithioerythritol (DTE) or dithiothreitol (DTT), for example in a concentration of about 80-400 mmol / l. The solubilization is conveniently carried out at room temperature, with one (incubation) lasting one to several hours, preferably two to 30 hours. In order to prevent oxidation of the reducing agent by the presence of oxygen in the air, the addition of EDTA may be appropriate. In addition to solubilization and reduction, the solubilization step has a purifying effect because most of the material that does not cross-react immunologically with t-PA (foreign proteins) does not become soluble.

8 95578

After solubilization and before the activation step, purification steps known per se and conventional can be carried out; purification methods include, for example, steric exclusion chromatography (SEC) (in the presence of guanidine hydrochloride or urea) or ion exchange (in the presence of urea or its derivatives). Nonspecific oxidation can be prevented again by the addition of a reducing agent (e.g., 2-mercaptoethanol) or by maintaining the pH at 4.5 (see, e.g., R. Rudolph, Biochem. Soc. Transactions 13. (1985) 308-311). If DTE is used in the previous dissolution step, it must be separated in one of the purification steps.

Purification can be performed, for example, by SEC chromatography using Sephadex G-100 gel, in the presence of guanidine hydrochloride and a reducing agent, e.g. GSH, at pH 1-4 (at this stage a large part of the foreign protein can be separated); or it can be carried out by separating the denaturant and the reducing agent so that the salts are removed on a Sephadex G-25 gel in a 0.01 mol / l HCl solution or in a 0.1 mol / l acetic acid solution. Alternatively, the denaturing agent and the reducing agent can be separated by dialysis against these same solutions.

After the reactivation step, a second purification step can be performed; the purification of this step is usually carried out by dialysis or isolation of the activated t-PA after this, for example by affinity chromatography, using, for example, a Lys-Sepharose gel.

According to the invention, t-PA derived from prokaryotes can be activated in such a way that, in addition to the normal biological activity, a stimulatability which is considerably higher than that of native t-PA is also achieved, as defined above. than 10-, even 50-fold.

9 95578

Another eukaryotic protein that can be activated according to the invention after expression in prokaryotes is interferon beta.

The essential features of the invention are set out in the appended claims.

The following examples further illustrate the invention without, however, limiting it in any way. Unless otherwise indicated, percentages are by weight and temperatures are in degrees Celsius.

Example 1 a) Preparation of "light refracting bodies" 15 100 g of moist cell mass of E. coli mixed with 1.5 liters of a solution containing 0.1 mol / l Tris-HCl (pH 6.5) and 20 mmol / l EDTA , was homogenized (Ultra-Turrax, 10) and 0.25 mg / ml lysozyme was added to the homogenate. The mixture was incubated for 20-30 minutes at room temperature, after which it was homogenized again and cooled to 3 ° C. The cells were disrupted by high pressure dispersion (550 kg / cm 2). The mixture was then rinsed with a further 300 ml of a solution containing 0.1 mol / l Tris-HCl (pH 6.5) and 20 mmol / l EDTA. The mixture was centrifuged (25 hours at 27,000 xg at 4 ° C for 2 hours), after which the pellet was stirred in 1.3 liters of a solution containing 0.1 M Tris-HCl (pH 6.5), 20 mmol / 1 EDTA and 2.5% Triton X-100 and homogenized. The mixture was centrifuged again (30 minutes at 27,000 xg at 4 ° C), after which the pellet was stirred in 1.3 liters of a solution containing 0.1 mol / L Tris-HCl (pH 6.5), mmol / l EDTA and 0.5% Triton X-100 and homogenized. Centrifugation of the pellet (30 minutes at 27,000 xg at 4 ° C) and homogenization in 1 liter of a solution containing 0.1 to 35 mol / l Tris-HCl (pH 6.5) and 20 mmol / l EDTA were repeated alternately. thrice.

The t-PA content in the preparation of "light refracting bodies" was quantified by SDS-PAGE, in which 40 t-PA bands were identified as "Western spots" and analyzed by densitometry. The "light-refracting bodies" produce a strong t-PA band with a molecular weight of about 60 kDa in the SDS-PAGE method and the "Western blot" method, with t-PA accounting for about 21% of the total protein content of the "light-refracting bodies". %.

b) Solubilization and reduction of "refractive bodies" 10 "Refractive bodies" were incubated at room temperature for 2-3 hours in a solution containing 0.1 mol / l Tris-HCl (pH 8.6), 6 mol / l guanidine hydrochloride, 0.15-0.4 mol / l DTE and 1 mmol / l EDTA and with a protein content of 1-5 mg / ml. Insoluble material-15 (cell wall bodies, etc.) was then separated by centrifugation (e.g., 35,000-550,000 x g for 30 minutes at 4 ° C). The pH of the supernatant was adjusted to 3 with concentrated hydrochloric acid HCl. The denaturing agent and reducing agent were then removed by dialysis at 4 ° C against a 0.01 mol / l HCl solution.

c) Reaoxidation and activation

Reacoxidation and activation were performed by diluting the mixture 1:50 to 1: 200 with a solution containing 0.1 M mol / L Tris / HCl (pH 10.5), 1 mmol / l EDTA, 1 mg / ml BSA, 0, 5 mol / l L-arginine, 2 mmol / l GSH, 0.2 mmol / l GSSG. Activation was allowed to proceed for 17-24 hours at a temperature of about 20 ° C, after which the yield was determined by comparing the activity to the activity of natural glycosylated t-PA from eukaryotes.

Yield calculated on the total protein content of the "light refracting bodies": 2.5 +/- 0.5% 35 Stimulability: 10 +/- 5%.

Yield based on the proportion of t-PA in "light refracting pieces": about 12%.

11 95578 d) Reacoxidation and activation without separation of denaturing agent and reducing agent "Refractive bodies" were incubated for 2 hours at room temperature in a solution containing 0.1 mol / l Tris / HCl (pH 8.6), 6 mol / l guanidine hydrochloride , 0.2 mol / l DTE and 1 mmol / l EDTA, and having a protein content of 1.25 mg / ml. The reoxidation was then started immediately by diluting 1: 100 with a solution containing 0.1 M Tris / HCl (pH 10.5), 1 M EDTA, 1 mg / ml BSA, 0.3 M L arginine and the amounts of GSSG shown in the table. In addition, guanidine hydrochloride was present in the activation mixture at a residual concentration of 0.06 mol / l and 2 mmol / l of DTE.

15

The following table shows the dependence of the activation yield on the GSSG concentration when the activation is carried out without separating the denaturing agent and the reducing agent.

20 GSSG Yield * Stimulability (mmol / l) (%) (coefficient) 0.2 0 1 0.13 4.0 25 5 1.49 7.4 6 1.28 5.4 7 1.04 5.8 9 0.98 5.2 10 1.77 10.0 30 15 0 20 0 = yield of active t-PA calculated from the total protein content of the "light-refracting 35 bodies".

95578 12

Example 2 A preparation of "refractive bodies" (VTK) (about 5 mg) was incubated at room temperature for 2-3 hours in 1 ml of a solution containing 0.1 mol / l Tris / HCl (pH 8.6), 6 5 mol / L guanidine hydrochloride and 0.15-0.2 mol / l DTE. The insoluble material (pieces of cell walls, etc.) was then separated by centrifugation (20 minutes at 17,000 x g). The denaturing agent and reducing agent were removed by gel filtration using Sephadex G-25 gel ("Sulo perfine") in 0.01 mol / L HCl solution. The sample was then diluted 5-10-fold. The reduced material was stored at -20 ° C in a 0.01 mol / L HCl solution.

15 Example 3

The following tables show the effect of several parameters of the invention on t-PA activation and stimulation. The protein solubilized and reduced according to Example 2 was not further purified for these reoxidation experiments.

The reduced protein (in 0.01 mol / L HCl solution) was activated by diluting it 1:10 to 1: 500 with "reoxidizing buffer". Activation was determined after 22-48 hours of incubation at room temperature. The activity of the reoxidized protein is calculated from the "reoxidation standard" (100%) in a solution containing:

0.1 mol / l Tris / HCl (pH 10.5) +1 mmol / l EDTA

+0.5 mol / l L-arginine + 1 mg / ml BSA

+ 0.5 mmol / l GSH (reduced glutathione) + 0.5 mmol / l GSSG (glutathione disulfide).

35

Stimulability is calculated by the formula AE + CNBrFSP AE-CNBrFSP (see W. Nieuwenhuizen et al., Biochimica et Biophysica Acta m 755 (1983) 531-533). The activity (as a percentage) and the stimulus (mt nm MIU) of 13,95578 (coefficient) were determined in J. H. Verheijen Thromb. Haemostas. 48 (3), 266-269, (1982).

5 The following results were obtained: 1. Dependence of the activation yield on the addition of L-arginine or guanidine hydrochloride: 10 Reoxidation in a solution containing 0.1 mol / l Tris / HCl (pH 10.5)

+ 1 mmol / l EDTA + 1 mg / ml BSA + 0.5 mmol / l GSH 15 +0.5 mmol / l GSSG

a) L-arginine L-arginine Activity Stimulability 20 (mol / l) (%) (coefficient) 0 4 2.5 0.25 98 7.5 0.5 100 21.9 25 0.75 27 16.3 1 .0 23 3.5 In this example, it should be noted that L-arginine 30 inhibits t-PA. Thus, in the case of higher L-arginine concentrations, the decrease in activation yield must be corrected in a manner corresponding to inhibition.

14 95578 b) Guanidine hydrochloride (Gdn / HCl) (Gdn / HCl) Activity (moles / l) (%) 5 ....................... .....

0 11 0.25 22 0.5 53 0.75 58 10 1.0 12 2. Dependence of activation yield on the addition of urea and urea derivatives: 15

Reaoxidation in a solution containing 0.1 mol / l Tris (pH 10.5), 1 mmol / l EDTA, 1 mg / ml BSA, 5 mmol / l GSH, 0.2 mmol / l GSSG.

20 a) Urea

Urea Activity (moles / l) (%) 25 0 1 0,5 20 1 59 1,5 126 2 162 30 2,5 141 3 72 4 12 5 0 35 15 95578 b) Methyl urea

Methyl urea Activity (moles / l) (%) 5 ------------------------------------- 0, 5 22 1 174 1.5 313 2 375 10 2,5 332 3 215 4 12 5 0 15 c) Ethyl urea

Ethyl urea Activity (moles / l) (%) 20 ------------------------------------- 0, 5 46 1 212 1.5 323 2 300 25 2,5 107 3 19 4 0 5 0 30 16 95578 d) Dimethyl urea

Dimethylurea Activity Stimulability (moles / l) (%) (coefficient) 5 ---------------------------------- ----------------------- 0.5 167 8.8 1 256 8.9 1.5 283 9.4 2 177 7.7 10 2.5 78 8.9 3 23 9.9 4 4 8.6 5 2 3.5 15 3. Dependence of activation yield on the addition of fatty acid amides:

Reoxidation in a solution containing 0.1 mol / l Tris (pH 10.5), 1 mmol / l EDTA, 1 mg / ml BSA, 5 mmol / l GSH, 0.2 mmol / l GSSG.

a) Formamide 25 Formamide Activity: (moles / l) (%) 0 42 0,5 59 30 1 175 1.5 245 2 325 2.5 423 3 444 35 4 416 5 341 ·> su -. * mtu. . ί 17 95578 (b) Methylformamide

Methylformamide Activity (moles / l) (%) 5 ------------------------------------- 0, 5 100 1 135 1.5 304 2 389 10 2,5 466 3 452 4 425 5 121 15 c) Acetamide

Acetamide Activity (moles / l) (%) 20 ------------------------------------- 0, 5 72 1 134 1.5 207 2 261 25 2.5 204: · 3 237 4 198 5 141 30 is 95578 d) Propionamides

Propionamide Activity (moles / l) (%) 5 ------------------------------------- 0, 5 95 1 99 1.5 197 2 150 10 2.5 101 3 39 4 2 5 0 15 e) Butyramide

Butyramide Activity (moles / l) (%) 20 ------------------------------------- 0, 5 55 1 52 1.5 17 2 0 25 ------------------------------------ 4. Dependence on activation yield The pH-value

Reaoxidation in a solution containing 0.1 mol / l Tris / HCl + 1 mmol / l EDTA + 0.5 mol / l L-arginine + 1 mg / ml BSA + 0.5 mmol / l GSH + 0.5 mmol / 1 GSSG 35 19 95578

Activity Stimulability pH (%) (factor) 7 1 58 22 3.0 9 89 13.6 10 105 20.3 11 95 21.3 10 5. Dependence of activation yield on GSH / GSSG concentration

Reoxidation in a solution containing 0.1 mol / l Tris / HCl, pH 10.5,

15 +1 mmol / l EDTA

+ 0.5 mol / l L-arginine + 1 mg / ml BSA

a) + 1 mmol / l GSH

20 (GSSG) Activity Stimulability (mmol / l) (%) (coefficient) 0.1 239 14.9 25 0.2 273 15.3 0.5 193 13.3 1 198 12.5 5 17 2.1 10 0 30 20 0 20 95578

b) + 0.2 mmol / l GSSG

(GSH) Activity Stimulability (imnols / 1) (%) (coefficient) 5 -------------------------------- ---------------- 0.05 15 2.2 0.1 40 3.8 0.2 112 6.8 0.5 142 7.4 10 1,273 6.8 5,260 7.9 10,143 6.3 20 55 5.1 15 6. Dependence of the activation yield on the protein content during reoxidation (dilution ratio 1:20 - 1: 500)

Reoxidation in a solution containing 0.1 mol / l Tris / HCl (pH 10.5)

+ 1 mmol / l EDTA +0.5 mol / l L-arginine + 1 mg / ml BSA + 0.5 mmol / l GSH 25 +0.5 mmol / l GSSG

Dilution Activity Stimulability (%) (factor) 30 1:10 29 15.3 1:20 45 25.4 1:50 69 37.9 1: 100 100 37.9 1: 200 79 52.7 35 1: 500 29 28.7 7. Dependence of activation yield on BSA supplement 95578 21

Reoxidation in a solution containing 0.1 mol / l Tris / HCl (pH 10.5)

5 +1 mmol / l EDTA

+ 0.5 moles of L-arginine + 0.5 mmol / l GSH + 0.5 mmol / l GSSG

10 BSA Activity (mg / ml) (%) 0 47 0.5 83 15 1 100 3 102 5 52 20 Figures 1 and 2 show the activity in the presence and absence of CNBr cleavage products of fibrin after reoxidation for 17 hours at room temperature, which the reoxidation was carried out in the following solution: 0.1 mol / l Tris / HCl (pH = 10.5) +1 mmol / l EDTA + 0.5 mol / L-arginine + 1 mg / ml BSA + 0.5 mmol / l GSH + 0.5 mmol / l GSSG. In Figures 1 and 2, curves (A) show activity in the presence of CNBr cleavage products, and curves (B) show activity in the absence of CNBr cleavage products.

30

Example 4

Activation of genetically engineered interferon beta "Light-refracting bodies" was prepared by the method described above. The reduction and solubilization of the "refractive bodies" was carried out as follows: the pellet was incubated for 3 hours at 25 ° C in 10 ml of a solution containing 9.1 mol / l Tris / HCl, pH 8.6, 6 mol / l. 95578 lia / l Gdn.HCl, 1 mmol / l EDTA and 0.2 mol / l DTE, the mixture was centrifuged at 48,000 xg for 30 minutes at 4 ° C, after which the pH of the supernatant was adjusted to 3 with concentrated hydrochloric acid HCl. The mixture was then gel-filtered using Sephadex G25 F gel in a 0.01 mol / L HCl solution.

The conductivity, protein content and reactivability of the eluent were determined.

10

The activity of the reoxidized protein is based on "standard activation" (= 100%) in a solution containing 0.1 mol / l Tris / HCl, pH 10.5, 1 mmol / l EDTA, 5 mmol / l GSH, 0.5 mmol / 1 GSSG and 0.25 mol / l L-arginine.

15 a) Dependence of activation yield on the addition of L-arginine

The eluent was diluted 1:50 with 0.1 M Tris / HCl, pH 8.5, 1 mmol / l EDTA, 5 mmol / l GSH, 0.5 mmol / l GSSG, and activated hours at 0 ° C.

Dependence of activation on L-arginine 25 L-arginine (moles / l) Activity (%) 0 8 0.25 8 0.5 15 30 0.75 15 b) Dependence of activation yield on urea addition 35 The activation solution corresponds to the solution according to a); however, activation was allowed to proceed for 17 hours at 0 ° C.

23

Dependence of activation on urea 95578

Urea (moles / l) Activity (%) 5 0 13 0,5 100 1 200 1,5 100 10 c) Dependence of activation yield on the addition of formamide

Activation was performed as described in a); samples were examined after activation progressed for 17 hours at 0 ° C.

Dependence of activation on formamide

Formamide Activity 20 (moles / l) 0 13 1 13 2 13 25 3 0 4 0 d) Dependence of activation yield on oxidation-reduction buffer 30

The eluent was diluted 1:50 with a solution containing 0.1 mol / L Tris-HCl, pH 8.5, 1 mmol / l EDTA and 0.25 mol / l L-arginine, and the samples were analyzed after activation. had progressed for 17 hours at 0 ° C.

Dependence of activation on GSH and GSSG

24 95578 GSH GSSG Activity (mmol / l) (mmol / l (%) 5 -------------------------------- ----------- 1 0,5 6 5 0,5 13 10 0,5 25 20 0,5 25 10 ------------------ ------------- -..............

5 0.1 13 5 0.5 13 5 1.0 13 5 5 6 15 ------------------------------ ---------- e) Dependence of activation yield on the addition of BSA

The eluent was diluted 1:50 with a solution of 0.1 mol / L Tris / HCl, pH 8.5, 1 mmol / l EDTA, 5 mmol / l GSH, 0.5 mmol / l GSSG and 0, 25 mol / l L-Arginine and was analyzed after activation of 011 for 17 hours at 0 ° C.

25 Dependence of activation on BSA

BSA (mg / ml) Activity (%) 0 13 30 1 13 2 25 5 13 35 f) pH dependence of activation yield

The eluent was diluted 1:50 with a solution containing 0.1 mol / l Tris / HCl, 1 mmol / l EDTA, 5 mmol / l 95578 GSH, 0.5 mmol / l GSSG and 0.25 mol / l L- arginine and was analyzed after 17 hours of activation at 0 ° C.

5 Dependence of activation on pH pH Activity (%) 6.5 0 10 7.5 6 8.5 13 9.5 50 10.5 100

Claims (21)

1. A method for activating by expression in prokaryotes genetically engineered heterologous eukaryotic proteins, which exhibit disulfide bridges, by digesting the prokaryote cells, solubilizing proteins under denaturing and reducing conditions, and reactivating under oxidizing conditions in the presence of the compounds GSH and GSSG, characterized in that in the reactivation step, the pH is up to 8-12, the GSH concentration is up to 0.1-10 20 mmol / l, the GSSG concentration to 0.01-3 mmol / 1 denaturing agent, selected from the group of arginine, methylurea, ethylurea, dimethylurea, formamide, methylformamide, acetamide, propionamide and butyramide, are used in a non-denaturing concentration. 15 Process according to Claim 1, characterized in that in the reactivation step the pH is added to 9.5-11. Process according to claim 1 or 2, characterized in that in the reactivation step the GSH concentration is in the range of 0.2-10 mmol / l and / or the GSSG concentration is in the range of 0.05-1 mmol / l. Process according to any of the preceding claims, characterized in that, after solubilization and prior to reactivation, a purification step is carried out. Process according to any of claims 1-3, characterized in that reactivation is carried out without first separating denaturing agent and reducing agent, diluting the reaction solution after denaturation and reduction with a reactivating buffer, and then following reactivation the GSSG concentration. exceeds the residual concentration of the compound DTE. 35 Method according to any of claims 1-5, characterized in that the expression is carried out in E. coli or P. puti-da bacteria. 95578 Process according to any of claims 1-6, characterized in that in the reactivation step, as the denaturing agent, arginine, guanidine hydrochloride and / or at least one compound of the general formula R 2 CO-NRR, (I), wherein R and R 5 represents H or alkyl group having 1-4 C atoms and R 2 represents H or NHR] or alkyl having 1-3 C atoms. 8. A process according to claim 7, characterized in that the concentration of arginine and / or guanidine hydrochloride is in the range of 0.1-1.0 mol / l, especially 0.25-0.8 mol / l. 9. A process according to claim 7, characterized in that the concentration of the compound of the general formula I is in the range 0.5-4 mol / l, especially 1-3.5 mol / l. 15 Method according to any of the preceding claims, characterized in that in the reactivation step one is employed in the presence of a non-proteolytically active protein, especially in the presence of bovine albumin. 20 Method according to any of the preceding claims, characterized in that the cell digestion is carried out by ultrasound, high pressure dispersion or lysozyme. 25 Process according to claim 11, characterized in that the digestion is carried out in a dilute aqueous buffer solution, especially in 0.1 mol / l Tris, at a neutral to slightly acidic pH. 30 13. Process according to any of the preceding claims, characterized in that after the cell attachment the insoluble constituents are separated. Process according to any of the preceding claims, characterized in that the solubilization step operates at an alkaline pH in the presence of a reducing agent from the mercapto group and in the presence of a denaturant. il i «» ΙιΜί liiti i 95578 Process according to claim 14, characterized in that the process is carried out in the presence of guanidine hydrochloride and / or a compound of general formula I as a denaturing agent. 5 Process according to claim 15, characterized in that the concentration of guanidine hydrochloride is up to 6 mol / l, and of the compound of the general formula I is up to 8 mol / l. 10 Process according to any of claims 14-16, characterized in that it is carried out in the presence of the compound DTE, β-mercaptoethanol, cysteine or the compound GSH. 15 18. Process according to any of the preceding claims, characterized in that purification and separation of reducing, oxidizing or denaturing agents is carried out by means of controlled exclusion chromatography or dialysis. 20 19. Process according to any of the preceding claims, characterized in that after the reactivation step a purification step is performed by dialysis. Method according to any of claims 1-19, characterized in that, as a genetically-engineered eukaryotic protein, t-PA protein is used. The method according to any of claims 1-19, characterized in that, as a genetically-engineered eukaryotic protein, β-interferon is used.